Pothranjenost kod pacijenata s rakom debelog crijeva i rakom gušterače : prevalencija i potrebe liječenja u jednogodišnjem razdoblju od kolovoza 2020. do kolovoza 2021.

Objectives: The aim of this study was to determine and compare the prevalence of malnutri-tion in pancreatic and colorectal cancer patients attending the outpatient clinic presenting for diagnosis, therapy or follow-up. Additionally, the study investigated the benefit of nutritional intervention, which includes oral nutritional supplements (ONS) and parenteral nutrition (PN) in the pancreatic cancer (PC) group and the colorectal cancer (CRC) group. Subjects and methods: 108 patients accounted for the whole study group comprising CRC (N = 57) and PC (N = 51) patients. All patients were pre-screened and if this was positive the main screening followed. This was performed by the dietitian with the NRS. Patients with a score <3 were rescreened 8 weeks later and patients with NRS ≥3 were assessed by the dieti-tian and the oncologists for malnutrition (BMI, weight loss, reduced skeletal muscle mass). 43% of the whole study group received an intervention (ONS or PN). 71% received ONS and/or PN in the PC group compared to just 17% in the CRC. At the end of the study patients’ weight, complaints and appetite were compared to first screening. These three variables were used to evaluate the benefit of the intervention. Results: From the overall 108 patients 71% were malnourished. In the PC group 67% were malnourished compared to 59% in the CRC group. There was no significant difference be-tween the two groups (P=0.593). However, in regard of low BMI, which was one variable defining malnutrition, 22% of PC patients presented with a low BMI in comparison to 7% of CRC patients (P=0.029). Comparing the weight loss (>5%), also one criterion of the defini-tion, there was a significant difference (P<0.001). 71% patients with PC and 17% of patients with CRC received an intervention (P<0.001). When looking at the outcome of benefit 43% of PC patients experienced a benefit after intervention compared to 14% in the CRC patients. Benefit was seen in both groups but there was no significant difference between them (P=0.162). Conclusions: As expected prevalence of malnutrition is higher in patients with pancreatic cancer compared to patients with colorectal cancer. Both groups benefit from intervention. Due to the high prevalence of malnutrition in the studied groups, all healthcare workers should be aware of the consequences caused by malnutrition as well as the importance of ear-ly interventions. Nutritional evaluation should be part of every cancer patient’s treatment.Ciljevi: Cilj ove studije bio je utvrditi i usporediti prevalenciju pothranjenosti kod pacijenata s rakom gušterače i rakom debelog crijeva koji posjećuju ambulante radi utvrđivanja dijagnoze, liječenja ili kontrole. Dodatno, studija je istražila koristi od prehrambene intervencije, što uključuje oralne dodatke prehrani (ONS) i parenteralnu prehranu (PN) u skupini s rakom gušterače (PC)i skupini s rakom debelog crijeva (CRC). Subjekti i metode: Cijela promatrana skupina sastojala se od 108 pacijenata, a sastojala se od pacijenata s CRC (N=57) i PC (N=51). Svi pacijenti bili su podvrgnuti predprobiru, a ako je ovaj bio pozitivan onda i glavnom probiru. Ovo je obavio nutricionist probirom prehrambenog rizika (NRS). Pacijenti s rezultatom 3 ponovo u probrani nakon 8 tjedana, a pacijente s NRS≥3 procijenili su nutricionist i onkolog u vezi pothranjenosti (indeks tjelesne mase (BMI), gubitak težine, smanjena koštano-mišićna masa). 43% cijele promatrane skupine primilo je neku intervenciju (ONS ili PN). 71% primilo je ONS i/ili PN u skupini PC, prema svega 17% u skupini CRC. Na kraju studije težina, pritužbe i apetit pacijenata uspoređeni su s prvim probirom. Pomoću ove tri varijable procijenjena je korist od intervencije. Rezultati: Od sveukupnih 108 pacijenata 71% bili su pothranjeni. U skupini PC pothranjeno je bilo 67% pacijenata u usporedbi s 59% u skupini CRC. Nije bilo značajne razlike između ove dvije skupine (P=0,593). Međutim, u vezi niskog BMI, koji je bio jedna od varijabli koje određuju pothranjenost, 22% pacijenata s PC pokazalo je nizak BMI u usporedbi sa 7% pacijenata s CRC (P=0,029). U usporedbi gubitka težine, što je još jedan kriterij ovog određenja, postojala je značajna razlika (P<0,001). Intervenciju je primilo 71% pacijenata s PC i 17% pacijenata s CRC (P